Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | OC-001 + unspecified PD-L1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| OC-001 | OC001|OC 001 | TNFRSF9 Antibody 36 | OC-001 is a monoclonal agonist antibody that targets TNFRSF9 (4-1BB; CD137), which potentially results in activation of T-cells and antitumor activity (Ann Oncol 33 (2022): S884). | |
| unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 133 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|